pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$RYTMRHYTHM PHARMACEUTICALS, INC.

$RYTM112.36-3.80%
Boston, MA, USupdated 2h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
4
marketed
1
phase 3
0
catalysts ytd
4
approvals ytd
1
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Phase 2: 2Marketed: 1Unknown: 1
2Phase 21Marketed1Unknown
Marketed
setmelanotide
Obesity
Phase 2
RM-718
Obesity
Phase 2
bivamelagon
Obesity
drug
IMCIVREE
1 INDICATIONS AND USAGE IMCIVREE is indicated to reduce e…
Melanocortin receptor 4

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 3, 2026
earnings
$RYTM112.36-3.80%
18d ago
RHYTHM PHARMACEUTICALS, INC. earnings
RHYTHM PHARMACEUTICALS, INC.
→
view all catalysts →

Active trials

  • phase3A Trial of Setmelanotide in Acquired Hypothalamic Obesityactive not recruitingn=143
  • phase3Open-Label Extension Study of Setmelanotidecompletedn=28
  • phase2A Study of Setmelanotide in Patients With Prader-Willi Syndromeactive not recruitingn=18
  • phase2A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesitycompletedn=28
  • phase3A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)recruitingn=39
  • phase2A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)enrolling by invitationn=25
  • phase3EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathwayactive not recruitingn=296
  • phase2A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairmentrecruitingn=150
🐶 Hiring Signal
No open roles indexed yet — view RHYTHM PHARMACEUTICALS, INC. jobs →

News

  • Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
    ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…
    biospace · 7d ago
  • Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
    AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.
    biospace · 15d ago
  • AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war
    AstraZeneca has made a roughly $10 billion offer to purchase rare obesity disease player Rhythm Pharmaceuticals, The Wall Street Journal reports. At least three teams of analysts suggest a bidding…
    fiercebiotech · 15d ago
  • Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data
    Plus news about Sanofi, PharmaMar, Jazz, Rhythm Pharmaceuticals, Spyre and Zymeworks 🇨🇳 Another obesity readout from China: Gan & Lee Pharmaceuticals, a China-based insulin specialist, announced…
    endpoints · 5mo ago
identifiers
ticker
$RYTM
SEC CIK
0001649904
country
US
source
sec_tickers
top tags
Obesity3
mentioned in
4news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?